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Abstract
Background: The leaves of Oxyanthus pallidus Hiern (Rubiaceae) are extensively used in the west region of
Cameroon as analgesic. These leaves are rich in cycloartanes, a subclass of triterpenes known to possess analgesic
and anti-inflammatory properties. The present study aimed at evaluating the analgesic properties of three
cycloartanes isolated from Oxyanthus pallidus leaves as well as their aglycones and acetylated derivatives.
Methods: Three cycloartanes OP3, OP5 and OP6 obtained by successive chromatography of the crude methanol
extract of the leaves were hydrolysed to yield respective aglycone AOP1, AOP2, AOP3 and acetylated to HOP1, HOP2
and HOP3 respectively. Formalin-induced pain model was used to evaluate the acute anti-nociceptive properties of
these cycloartanes (5 mg/kg, p.o) in mice and to determine the structure-activity relationship. Acute (24 h) and
chronic (10 days) anti-hyperalgesic and anti-inflammatory activities of OP5 were evaluated at the doses of 2.5 and
5 mg/kg/day administered orally. OP6 was also evaluated in acute experiments. The antioxidant and hepato-
protective activities of OP5 were evaluated at the end of the chronic treatment.
Results: The mixture and the individual isolated cycloartanes significantly inhibited both phases of formalin-
induced pain with percentage inhibition ranging from 13 to 78 %. Acid hydrolysis did not significantly affect their
antinociceptive activities while acetylation significantly reduced the effects of these compounds during the second
phase of pain. OP5 and OP6 induced acute anti-hyperalgesic activity in formalin-induced mechanical hyperalgesia
but not an anti-inflammatory effect. Repeated administration of OP5 for 10 days did not induce any anti-
hyperalgesic effect. The evaluation of in vivo antioxidant properties showed that OP5 significantly reduced
malondialdehyde and increased superoxide dismutase levels in liver without significantly affecting other oxidative
stress and hepatotoxic parameters. Chronic administration of OP5 did not cause gastric ulceration.
Conclusion: Cycloartanes isolated from Oxyanthus pallidus possess analgesic effects but lack anti-inflammatory
activities. This analgesic effect especially on inflammatory pain may be due to the presence of hydroxyl group in
front of the plane. OP5 is devoid of ulcerogenic effect and possess antioxidant properties that might be of benefit
to its analgesic properties.
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Background
Pain is known as a major public health threat not only be-
cause it underlies almost every illness but also because it
has become an illness by himself. It is therefore one of the
leading causes of medical consultation [1], with enormous
socio-economic and physiological deleterious impacts.
Therefore, there is a high need to properly handle this ail-
ment especially at its chronic stage. Huge progress has
been made in recent years in order to first understand the
pathology and secondly to master the therapeutic aspects
and treatment. For the last purpose, a large number of
therapeutics molecules like opioids, non-steroidal and
steroidal analgesics have been developed. But existing
therapeutics have some disadvantages such as their ineffi-
cacy, the resistance of some pathologies and the side ef-
fects, especially gastrointestinal, hepatic or renal toxicity.
For instance, patients with severe inflammatory diseases
respond poorly to conventional doses of corticosteroids
[2, 3]. One of the exciting strategies to overcome these
problems is to search for new and better drugs with min-
imal adverse effects. An important field of investigation to
discover new therapeutic molecules that can treat more
efficiently pain is that of secondary metabolites present in
medicinal plants. In fact phytopharmacological research
has brought substantial contribution to drug innovation.
In addition, chemical structural modification of molecules
has been shown to strongly modify the biological activity
of initial compounds. In fact, the analgesic activity of a
good number of chemical has been improved by their
structural modification [4–6].
Triterpenes constitute a class of secondary metabolites
that have shown potent analgesic and anti-inflammatory
activities [7–9], one of the subclass being cycloartanes.
The lasts molecules are secondary metabolites belonging
to the class of tetracyclic triterpenes and are synthesized
by many plant species. Cycloartanes possess various bio-
logical activities including anti-tumour, anti-virus, anti-
bacterial, anti-inflammatory, analgesic or antioxidant
activities [10, 11]. They therefore, offer an alternative in
the treatment of pain.
Ayatollahi et al. [12] showed that cycloartanes are able
to deactivate protein kinase C (PKC) and that this effect
could be attributed to the presence of hydroxyl group in
their molecular structures. Knowing the pivotal role that
PKC plays in the transduction of pain [13, 14], we hy-
pothesized that cycloartanes may possess good analgesic
activity related to the presence of hydroxyl group.
The present study evaluates the analgesic and anti-
inflammatory activities of three cycloartane glycosides,
named pallidioside A (OP3), pallidioside B (OP5) and palli-
dioside C (OP6) isolated from the leaves of Oxyanthus
pallidus, a plant extensively used in the West region of
Cameroon as analgesic. In attempt to determine the im-
portance of the glycoside moiety and the hydroxyl group in
the biological activity of these compounds, the effects of
their respective aglycone (AOP1, AOP2, AOP3) and acety-
lated (HOP1, HOP2, HOP3) derivatives were also evaluated.
Methods
Animal
Male and female rats of the Wistar strain aged 3 months
and weighing between 180 and 200 g and Swiss mice of
both sexes, aged 3 months and weighing between 20 and
30 g were used in this study. These animals were bred in
the animal house of the Laboratory of Animal Physiology
and Phytopharmacology of the University of Dschang
under a 12-h light/dark cycle with free access to standard
commercialized rodent diet and water. The number of
animals used was the minimum possible to determine
consistent effects of the drug treatments (See figures). All
protocols were submitted and approved by the local Ethics
Committee “The Animal Ethics Committee of the
University of Dschang” and conformed to the guidelines
for the study of pain in awake animals established by the
International Association for the Study of Pain.
Plant collection and extraction
Collection and isolation of major compounds
Oxyanthus pallidus materials were harvested in November
in Dschang in the Western region of Cameroon. The plant
was identified at the National Herbarium of Cameroon in
Yaounde by Mr. Victor Nana, in comparison to an existing
Voucher specimen no 7335/SFR/CAM. The leaves were
subsequently dried at room temperature and then crushed.
The resulting powder was extracted by soaking in methanol
for 24 h. After filtration and evaporation at 70 °C under re-
duced pressure, the extract obtained was subsequently sub-
jected to repeated column chromatography silica gel, which
allowed to isolate and identify the three main compounds
pallidiosides A (OP3), pallidiosides B (OP5) and pallidiosides
C (OP6) as previously described [15].
Preparation of aglycone derivatives
One point five gram of each compound (OP3, OP5 and
OP6) was individually refluxed in methanol/H2SO4 10 %
(25 ml) at room temperature for 48 h. Reaction mixture
was neutralized by sodium hydroxide solution (6 N) and
extracted with CHCl3 (3 × 10 ml). Each organic phase
was concentrated under vacuum to give residues (560,
530 and 540 mg respectively) which were separately sub-
jected to CC over silica gel with hexane/AcOEt (1:1) as
the eluent to yield AOP1, AOP2 and AOP3 compounds
(350, 335 and 340 mg respectively).
Preparation of acetylated derivatives
Two hundred and fifty milligrams of each compound
(OP3, OP5 and OP6) were individually acetylated with
Ac2O–pyridine (2:1) v/v at room temperature for 24 h,
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and each of the reaction mixture was purified over silica
gel column, eluted with the hex-EtOAc (50 %) mixture
to give the corresponding acetylated derivatives HOP1,
HOP2 and HOP3 (270, 280 and 285 mg respectively).
Pharmacological tests
Spontaneous pain induced by formalin in mice
This experiment followed the procedure previously de-
scribed [16]. Animals were orally treated (gavage) with the
mixture of the three cycloartanes (5, 10 and 20 mg/kg), in-
dividual isolated compounds (5 mg/kg) or derivatives
(5 mg/kg). Diclofenac given orally at 5 mg/kg was used as
positive control while the negative control group received
0.9 % NaCl solution. All the oral administered substances
were given at equivalent volume of 0.5 ml/30 g body
weight. One hour after administration of different sub-
stances, pain was induced by injecting 20 μL of formalin
(2.5 % in saline) under the aponeurosis of the dorsal
surface of the right hind paw of each animal. They were
individually observed and pain evidenced by licking,
flinching or biting the injected paw was quantified using
an electronic timer, in two periods. The first period con-
sisted of the first 5 min indicating neurogenic pain and
second period (15th to 45th minute) corresponding to the
tonic inflammatory pain.
Mechanical hyperalgesia and inflammation induced by
formalin in rats
In an attempt to evaluate the time-dependent analgesic
and anti-inflammatory effects, OP5 and OP6 were tested
Fig. 1 Structures of the main cycloartanes (pallidioside A: OP3, pallidioside B: OP5 and pallidioside C: OP6) isolates from the leaves of Oxyanthus pallidus
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acutely in formalin-induced pain. The effect of 10 days re-
peated administration of OP5 (2.5 and 5 mg/kg/day as a
single bolus) was also tested. NaCl 0.9 % and diclofenac
were respectively used for negative and positive controls.
One hour after oral administration of various substances,
pain and inflammation were induced by injecting 0.1 ml
of a 2 % formalin solution, under the left hind paw of each
rat [17]. Ugo Basile analgesy meter no. 372157 and the
caliper were used to measure the response threshold of
each animal to mechanical pain and the paw diameter, re-
spectively. The response threshold of the animal to mech-
anical pain was reported before treatment and 1, 2, 4, 6, 8
and 24 h post injection for the first day and once a day for
ten days. The diameter of the injected paw was mea-
sured before treatment and 3, 5, 7 and 24 h post injec-
tion for the first day and then once a day for ten days.
For repeated treatments, drugs were administered once
a day, after collection of data. At the end of the experi-
ment, the antioxidant, hepatotoxic and ulcerogenic ef-
fects of chronic administration of OP5 were examined.
On this purpose, animals were sacrificed on day 11.
Blood, kidney and liver samples were collected. Serum
was separated for ALAT and ASAT assays. Kidney and
liver were homogenized in Tris buffer and centrifuged.
The supernatant was used to assay nitric oxide, malondial-
dehyde, superoxide dismutase, catalase and glutathione.
Fig. 2 Structures of respective aglycones (AOP1, AOP2, AOP3) and acetylated (HOP1, HOP2 and HOP3) derivatives of OP3, OP5 and OP6
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Immediately after blood, liver and kidney collection, the
stomach was carefully dissected out and opens along the
great curvature. The mucus weight and ulceration index
were estimated as previously described [18].
Biochemical analysis
To assess whether different treatments could induce
liver damage, enzymatic activities of aspartate amino-
trasferase (AST) and alanine aminotrasferase (ALT)
were measured in serum following the commercial kit
(Immesco) procedure. SOD was evaluated based on its
ability to inhibit or retard the autoxidation of adrenaline
to adrenochrome in basic medium [19]. To assess
whether the tested compound could inhibit lipid peroxi-
dation, the amount of malondialdehyde was assayed in
homogenates of liver and kidney. The protocol followed
was as previously described by Ohkawa et al. [20].
Glutathione concentration and catalase activity in tis-
sues homogenates were measured according to the
methods described by Dimo et al. [21]. NO content in
the homogenates of kidney and liver was measured,
using Fiddler’s method [22].
Table 1 1H (600 MHz, MeOD) and 13C (150 MHz, MeOD) data of AOP1, AOP2 and AOP3
Positions AOP1 AOP2 AOP3
δC δH (mult, J(Hz) δC δH (mult, J(Hz) δC δH (mult, J (Hz)
1 31.5 1.33 (1H, m, Hβ), 1.61 (1H, m, Hα) 31.3 1.33 (1H, m, Hβ), 1.60 (1H, m, Hα) 31.3 1.33 (1H, m, Hβ), 1.62 (1H, m, Hα)
2 30.5 1.64 (1H, m, Hα), 1.73 (1H, m, Hβ) 29.4 1.64 (1H, m, Hα), 1.73 (1H, m, Hβ) 29.4 1.63 (1H, m, Hα), 1.72 (1H, m, Hβ)
3 79.1 3.17 (dd, 4.6, 10.1) 77.7 3.24 (dd, 4.4, 11.1) 78.0 3.17 (dd, 4.5, 10.1)
4 41.2 39.8 / 39.8 /
5 45.6 1.51 (dd, 3.7, 13.1) 45.7 1.52 (dd, 3.9, 13.1) 45.7 1.51 (dd, 3.8, 12.1)
6 29.3 1.04 (1H, m, Hα), 1.74 (1H, m, Hβ) 30.7 1.04 (1H, m, Hα), 1.74 (1H, m, Hβ) 30.7 1.03, (1H, m, Hα), 1.74 (1H, m, Hβ)
7 70.1 3.50 ddd (4,0, 7.1, 12.6) 70.0 3.50 ddd (4,0, 7.1, 12.7) 70.0 3.50 (ddd, 4.0, 9.4, 13.3)
8 54.4 1.72 (1H, d, 7.0) 54 .2 1.71 (1H, d, 6.0) 54.2 1.72 (1H, d, 6.0)
9 26.6 26.5 / 26.5 /
10 19.7 19.6 / 19.7 /
11 26.0 1.31 (1H, m, Hα), 1.90 (1H, m, Hβ) 26.0 1.31 (1H, m, Hα), 1.92 (1H, m, Hβ) 26.0 1.30 (1H, m, Hα), 1.92 (1H, m, Hβ)
12 32.8 1.61 (1H, m, Hα), 1.68 (1H, m, Hβ) 32.4 1.63 (1H, m, Hα), 1.69 (1H, m, Hβ) 32.3 1.62 (1H, m, Hα), 1.68 (1H, m, Hβ)
13 45.3 45.4 / 45.4 /
14 46.0 46.0 / 46.0 /
15 48.8 1.64 (1H, dd, 5.2, 7.5, Hβ), 2.25
(1H, dd, 5.2 7.5, Hα)
48.8 1.66 (1H, dd, 5.2, 7.6, Hβ), 2.25
(1H, dd, 5.2, 7.6, Hα)
48.8 1.67 (1H, dd, 5.2, 7.7, Hβ), 2.25
(1H, dd, 5.2, 7.7, Hα)
16 72.1 4.43 (1H, ddd, 5.2, 7.5, 7.8) 72.1 4.44 (1H, ddd, 5.2, 7.6, 7.9) 72.0 4.43 (1H, ddd, 5.2, 7.6, 7.9)
17 55.8 1.63 (1H, dd, 7.8, 12.3) 55.9 1.64 (1H, dd, 7.9, 12.4) 55.8 1.63 (1H, dd, 7.9, 12.4)
18 17.2 1.20 (3H, s) 17.3 1.22 (3H, s) 17.2 1.21 (3H, s)
19 27.9 0.19 (1H, d, 4.0, Hα), 0.87 (1H, d, 4.0, Hβ) 27.9 0.19 (1H, d, 4.0, Hα), 0.85
(1H, d, 4.0, Hβ)
27.9 0.75 (1H, d, 4.0, Hα), 0.86
(1H, d, 4.0, Hβ)
20 30.1 1.81 (1H, m) 28.4 1.92 (1H, m) 28.5 1.82 (1H, m)
21 17.5 0.99 (1H, d, 7.6) 17.6 0.99 (1H, d, 7.6) 17.5 1.00 (1H, d, 7.6)
22 31.1 1.26 (1H, m, Hα),, 1.82 (1H, m, Hβ) 32.3 1.24 (1H, m, Hα), 1.82
(1H, m, Hβ)
32.5 1.22(1H, m, Hα),, 1.92(1H, m, Hβ)
23 28.3 1.63 (1H, m, Hα), 1.70 (1H, m, Hβ) 27.0 1.63 (1H, m, Hα), 1.72
(1H, m, Hβ)
28.0 1.62 (1H, m, Hα), 1.72 (1H, m, Hβ)
24 218.9 77.0 3.40 (1H, dd, 5.1, 12.0) 79.3 3.25 (1H, dd, 4.9, 11..3)
25 77.8 72.4 / 72.4 /
26 26.8 1.19 (3H, s) 24.0 1.19 (3H, s) 24.3 1.19 (3H, s)
27 26.8 1.17 (3H, s) 23.9 1.17 (3H, s) 23.4 1.16 (3H, s)
28 26.0 0.98 (3H, s) 24.6 0.98 (3H, s) 24.6 0.98 (3H, s)
29 13.2 0.86 (3H, s) 13.1 0.84 (3H, s) 14.9 0.86 (3H, s)
30 18.5 0.97 (3H, s) 18.4 0.97 (3H, s) 18.4 0.97 (3H, s)
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Statistical analysis
Results are expressed as Mean ± SEM (Standard Error of
the Mean). One-way ANOVA followed by the Turkey’s
post test was used to compare the averages for the various
groups in the antinociceptive tests in mice and in
biochemical analysis. Two-way ANOVA followed by Bon-
ferroni post-test was used to compare different groups in
the antihyperalgesic and the inflammatory tests. These
analyses were performed with the aid of Graph Pad Prism
software version 5.0.
Table 2 1H (500 MHz, MeOD) and 13C (150 MHz, MeOD) data of HOP1, HOP2 and HOP3
Positions HOP1 HOP2 HOP3
δC δH (mult, J(Hz) δC δH (mult, J(Hz) δC δH (mult, J (Hz)
1 30.4 1.40 (1H, m, Hβ), 1.60 (1H, m, Hα) 29.1 1.62 (1H, m, Hβ), 1.72 (1H, m, Hα) 29.1 1.62 (1H, m, Hβ), 1.72 (1H, m, Hα)
2 29.1 1.62 (1H, m, Hα), 1.73 (1H, m, Hβ) 27.0 1.43 (1H, m, Hα), 1.62 (1H, m, Hβ) 27.0 1.43 (1H, m, Hα), 1.62 (1H, m, Hβ)
3 77.8 3.22 (dd, 4.4, 11.1) 77.8 3.23 (dd, 4.2, 10.9) 77.8 3.23 (dd, 4.2, 10.9)
4 39.8 / 39.8 / 39.8 /
5 44.3 1.42 (dd, 3.9, 13.3) 44.2 1.45 (dd, 3.9, 13.1) 44.2 1.45 (dd, 3.9, 13.1)
6 28.1 1.08 (1H, m, Hα), 2.13 (1H, m, Hβ) 28.1 1.10 (1H, m, Hα), 2.13 (1H, m, Hβ) 28.1 1.10 (1H, m, Hα), 2.13 (1H, m, Hβ)
7 80.0 3.63 (ddd (4,0, 7.63, 12.6) 80.0 3.63 (ddd (4,0, 7.1, 12.7) 80.0 3.63 (ddd (4,0, 7.1, 12.7)
8 50.2 2.09 (1H, d, 7.63) 50.0 2.11 (1H, d, 6.0) 50.0 2.11 (1H, d, 6.0)
9 20.1 / 20.2 / 20.2 /
10 26.4 / 26.4 / 26.4 /
11 26.5 1.33 (1H, m, Hα), 1.90 (1H, m, Hβ) 30.3 1.42 (1H, m, Hα), 1.62 (1H, m, Hβ) 30.3 1.42 (1H, m, Hα), 1.62 (1H, m, Hβ)
12 32.3 1.60 (1H, m, Hα), 1.68 (1H, m, Hβ) 32.4 1.60 (1H, m, Hα), 1.69 (1H, m, Hβ) 32.4 1.60 (1H, m, Hα), 1.69 (1H, m, Hβ)
13 46.4 / 46.4 / 46.4 /
14 45.3 / 45.3 / 45.3 /
15 46.6 1.64 (1H, dd, 5.0, 7.5, Hβ), 2.33 (1H,
dd, 5.0 7.5, Hα)
46.4 1.63 (1H, dd, 5.2, 7.6, Hβ), 2.31 (1H, dd,
5.2, 7.6, Hα)
46.4 1.63 (1H, dd, 5.2, 7.6, Hβ), 2.31 (1H, dd,
5.2, 7.6, Hα)
16 71.9 4.46 (1H, ddd, 5.0, 7.6, 7.8) 72.3 4.43 (1H, ddd, 5.2, 7.6, 7.9) 72.3 4.43 (1H, ddd, 5.2, 7.6, 7.9)
17 56.0 1.62 (1H, dd, 7.7, 12.2) 56.0 1.64 (1H, dd, 7.9, 12.4) 56.0 1.64 (1H, dd, 7.9, 12.4)
18 16.2 1.18 (3H, s) 16.1 1.20 (3H, s) 16.1 1.20 (3H, s)
19 24.9 0.20 (1H, d, 4.5, Hα) 0.85 (1H, d, 4.5,
Hβ)
24.7 0.18 (1H, d, 4.6, Hα), 0.87 (1H, d, 4.6,
Hβ)
24.7 0.18 (1H, d, 4.6, Hα), 0.87 (1H, d, 4.6,
Hβ)
20 29.7 1.72 (1H, m) 28.5 1.95 (1H, m) 28.5 1.91 (1H, m)
21 17.0 0.97 (1H, d, 7.6) 17.2 0.97 (1H, d, 7.6) 17.2 0.97 (1H, d, 7.6)
22 32.9 2.78 (1H, m, Hα), 2.86 (1H, m, Hβ) 32.4 1.22 (1H, m, Hα), 1.81 (1H, m, Hβ) 32.4 1.82 (1H, m, Hα), 1.01 (1H, m, Hβ)
23 29.5 1.21 (1H, m, Hα), 1.97 (1H, m, Hβ) 30.3 1.42 (1H, m, Hα), 1.62 (1H, m, Hβ) 31.3 2.12 (1H, m, Hα), 1.12 (1H, m, Hβ)
24 218.1 / 77.0 3.36 (1H, dd, 5.1, 12.0) 79.5 3.46 (1H, dd, 5.1, 12.0)
25 76.5 / 71.9 / 71.9 /
26 25.4 1.32 (3H, s) 25.4 1.32 (3H, s) 25.4 1.32 (3H, s)
27 24.8 1.00 (3H, s) 24.0 1.18 (3H, s) 24.5 1.18 (3H, s)
28 24.9 1.00 (3H, s) 24.9 1.00 (3H, s) 24.9 1.00 (3H, s)
29 12.2 0.82 (3H, s) 12.8 0.82 (3H, s) 12.8 0.82 (3H, s)
30 18.5 0.96 (3H, s) 18.5 0.94 (3H, s) 18.5 0.94 (3H, s)
1’ 102.6 4.36 (1H, d, 7.8) 102.6 4.35 (1H, d, 7.7) 102.5 4.35 (1H, d, 7.7)
2’ 73.9 3.18 (1H, dd, 7.8, 8.8) 73.9 3.18 (1H, dd, 7.7, 8.7) 73.9 3.18 (1H, dd, 7.7, 8.7)
3’ 76.9 3.37 (1H, dd, 8.5, 8.8) 76.9 3.40 (1H, dd, 8.7, 9.0) 76.9 3.40 (1H, dd, 8.7, 9.0)
4’ 70.2 3.28 (1H, dd, 8.5, 9.0) 70.2 3.27 (1H, dd, 9.0, 9.2) 70.2 3.27 (1H, dd, 9.0, 9.2)
5’ 73.7 3.48 (1H, m) 73.7 3.48 (1H, m) 73.7 3.48 (1H, m)
6’ 63.9 4.11 (1H, dd, 2.1, 11.9), 4.48 (1H, dd,
2.1, 11.9)
63.9 4.11 (1H, dd, 2.0, 12.0), 4.48 (1H, dd,
2.0, 12)
63.9 4.11 (1H, dd, 2.0, 12.0), 4.48 (1H, dd,
2.0, 12)
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Results
Cycloartanes
The individual main compounds are all characterized by
the same basic structure and differ only on carbon 24.
This carbon atom, bearing one α-OH in OP5 and one β-
OH in OP6 respectively, was oxidized in ketone in mol-
ecule OP3 (Fig. 1).
1H and 13C data of these compounds
were previously described by Tigoufack et al. [15].
The aglycons derivatives generally have the same basic
structure as the main compound from which they de-
rived except the fact that, carbon atom C-7 which was
linked to a glucosyl moiety in each precursor, was now
linked to a β-OH group as indicated in Fig. 2.
AOP1 was obtained as a white powder. [α]D23 = + 85
(CH3OH, c = 0.92); IR (NaCl) νmax (cm
−1): 3375 (OH),
1703 (C =O), 1246 (C-O), 1H and 13C NMR data see
Table 1. HR-TOFESIMS m/z: 513.3717 [M +Na]+ (calcd.
For C30H50O5Na, 513.3712).
AOP2 was obtained as a white powder. [α]D23 = + 58.6
(CH3OH, c = 0.89); IR (NaCl) νmax (cm
−1): 3465 (OH),
1249 (C-O), 1H and 13C data, see Table 1; HR-
TOFESIMS m/z: 515.3719 [M +Na]+ (calcd. For
C30H52O5Na, 515.3712).
AOP3 was obtained as a white powder. [α]D23 = + 34.2
(CH3OH, c = 1.20); IR (NaCl) νmax (cm
−1): 3477 (OH),
1250 (C-O), 1H and 13C data, see Table 1; HR-
TOFESIMS m/z: 515.3719 [M +Na]+ (calcd. For
C30H52O5Na, 515.3712).
The acetylated derivatives generally have the same
basic structure as the main compound from which
they derived except the fact that all primary and sec-
ondary hydroxyl groups were acetylated as showed in
Fig. 2.
HOP1 was obtained as a white powder. [α]D23 = + 18.2
(CH3OH, c = 0.482 × 10
−2); IR (NaCl) νmax (cm
−1): 3450
(OH), 1249 (C-O), 1715 (C =O). 1H and 13C data, see
Table 2.
HOP2 was obtained as a white powder. [α]D23 = + 34.2
(CH3OH, c = 0.487 × 10
−2); IR (NaCl) νmax (cm
−1): 3450
(OH), 1250 (C-O), 1713 (C =O). 1H and 13C data, see
Table 2.
HOP3 was obtained as a white powder. [α]D23 = + 20.2
(CH3OH, c = 0.458 × 10
−2); IR (NaCl) νmax (cm
−1): 3477
(OH), 1249 (C-O), 1718 (C =O). 1H and 13C data, see
Table 2.
Effect of the mixture and isolated cycloartanes on
formalin-induced pain in mice
Treatment with different doses of the mixture of
cycloartanes significantly reduced the pain behavior
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Fig. 3 Effect of mixed (OPM) and isolated (pallidioside A: OP3, pallidioside B: OP5 and pallidioside C: OP6) cycloartanes on the first (panels a and c)
and second (panels b and d) phases of formalin-induced pain in mice. Each bar represents the mean ± SEM, n = 6. *P < 0.05, **p < 0.01, ***p <
0.001 significant difference as compared to control group. Diclo: diclofenac
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during the first and the second phases of pain induced
by formalin as compared to the control group. The
percentages of inhibition ranged from 51.33 to 65.15 %
for the first phase (Fig. 3a) and from 45.15 to 61.42 %
for the second phase (Fig. 3b). The highest percentages
of inhibition were obtained at 5 mg/kg during the first
phase and 20 mg/kg in the second. Concordantly, sys-
temic oral administration of the three main com-
pounds (OP3, OP5 and OP6) significantly (p <0.001)
reduced the licking time of the paw during the first
phase. No significant difference was observed between
the effect of mixture and the individual compounds
(Fig. 3c). OP5 reduced pain behavior by about 13 %
during the second phase but this effect missed
significance (p > 0.05), while OP3 and OP6 exhibited
significant analgesic effect similar to that of diclofenac
(Fig. 3d).
Effect of OP3, its aglycone (AOP1) and acetylated (HOP1)
derivatives on formalin-induced pain in mice
As shown in Fig. 4, oral administration of OP3 and its
derivatives exhibited an effective analgesic effect on both
phases of pain. There was no significant difference be-
tween the effect of OP3 and its derivatives during the
first phase (Fig. 4a). At the second phase OP3 and deriv-
atives also showed a significant analgesic effect but a sig-
nificant difference was observed between the effect of
the two OP3 derivatives, the aglycone AOP1 being











































Fig. 4 Effect of pallidioside A (OP3), its aglycone (AOP1) and
acetylated (HOP1) derivatives on the first (panel a) and second
(panel b) phases of formalin-induced pain in mice. Each bar
represents the mean ± SEM of six animals. *p < 0.05, **p < 0.01,
***p < 0.001 significant different compared to the control. αp < 0.05
significant difference between the two groups. Diclo: diclofenac
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Fig. 5 Effect of pallidioside B (OP5), its aglycone (AOP2) and acetylated
(HOP2) derivatives on the first (panel a) and second (panel b) phases of
formalin-induced pain in mice. Each bar represents the mean ± SEM,
n= 6. **P <0.01, ***p <0.001 significant difference compared to control.
αp < 0.05 significant difference between the two groups. Diclo: diclofenac
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significantly (p <0.05) more active than the acetylated
HOP1 (Fig. 4b).
Effect of OP5, its aglycone (AOP2) and acetylated (HOP2)
derivatives on formalin-induced pain in mice
Although OP5 and its derivatives all induced a signifi-
cant analgesic effect on the first phase of pain induced
by intraplantar administration of formalin, the acetylated
derivative was significantly less potent than OP5 and its
aglycone (Fig. 5a). On the second phase, OP5 and its
acetylated derivative did not show significant analgesic
effect as compared to control but AOP2 was significantly
active as compared both to the control and HOP2
treated groups (Fig. 5b).
Effect of OP6, its aglycone (AOP3) and acetylated (HOP3)
derivatives on formalin-induced pain in mice
OP6 and its two derivatives exhibited significant anal-
gesic effect on the first phase of pain induced by forma-
lin. Meanwhile, OP6 proved to be more effective than
any of its derivatives (Fig. 6a). This was more marked at
the second phase were AOP3 and HOP3 lacked signifi-
cant activity. However, OP6 was significantly active as
compared both to the control group and the HOP3
treated group (Fig. 6b).
Effect of OP5 and OP6 on mechanical hyperalgesia
and inflammation induced by formalin in rats
Systemic oral administration of OP5 and OP6 one hour
before induction of pain both produced significant
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Fig. 6 Effect of pallidioside C (OP6), its aglycone (AOP3) and acetylated
(HOP3) derivatives on the first (panel a) and second (panel b) phases of
formalin-induced pain in mice. Each bar represents the mean ± SEM,
n= 6. ***p <0.001 significant differences compared to the control.
αp < 0.05 significant difference between the two groups. Diclo: diclofenac
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Fig. 7 Time-dependant acute (panel a) effect of Pallidioside B (OP5)
and Pallidioside C (OP6) and repeated treatment of OP5 (panel b) on
mechanical pain induced by Randal sellito in rat paw injected with
formalin (2 %, 100 μl). Animals were orally treated with different
compounds and injected one hour later in the paw with formalin.
Pain threshold was measured before treatment and after formalin
injection. For chronic experiment, animals were daily treated and
pain threshold was measured before drug administration. Each point
represents the mean ± SEM, n = 8. *P < 0.05, **p < 0.01, ***p < 0.001
significant differences compared to the control. Diclo: diclofenac
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inhibition of hyperalgesia for up to 24 h. The acute max-
imal effect was observed 8 h post induction with OP6 at
the dose of 5 mg/kg as compared to the negative control
(Fig. 7a). This effect was similar to that of diclofenac at
the same dose. During the 10 days treatment, OP5 at
both doses shows significant effect only at the first day
(Fig. 7b).
As shown in Fig. 8, OP6 instead increase the in-
flammation induced by formalin. The inflammation
was significantly reduced by OP5 at the dose of
5 mg/kg at the third hour post induction. Repeated
administration of OP5 at both doses did not show
any anti-inflammatory activity all along the 10 days of
experiment.
Biochemical analyses
Results of the assays of oxidative stress parameters are
presented in Table 3. After 10 days of repeated treat-
ment, OP5 significantly reduced the malondialdehyde
production and increased the superoxide dismutase ac-
tivity in the liver, but has no effect on these parameters
in the kidney. OP5 did not affect the concentration of
NO, glutathione and the activity of catalase both in the
liver and kidneys. The concentration of ALAT dose-
dependently increased in the serum of OP5 treated ani-
mals as compared to the control group. Meanwhile, the
effect was not statistically significant.
Ulcerogenic activity
It is observed from Table 4 that after 10 days treatment,
animals treated with OP5 at both doses showed no ulcer-
ation in their gastric mucosa. Ulceration was recorded in
all animal treated with diclofenac with a percentage ulcer-
ated surface of 15.95 %. It was also observed that repeated
administration of diclofenac at the dose of 5 mg/kg/day
significantly reduced the mucus production, whereas OP5
has no effect.
Discussion
This work was undertaken to evaluate the analgesic and
anti-inflammatory effects of three cycloartanes isolated
from Oxyanthus pallidus and their derivatives. The mix-
ture of cycloartanes significantly inhibited both phases
of pain induced by the injection of formalin. When
tested individually, isolated compounds exhibited differ-
ent intensities of activity. During the first phase of pain,
the three compounds showed significant antinociceptive
effect. No significant difference was observed between
their effects although OP5 was nominally the most ef-
fective. Regarding the second phase of pain, OP3 and
OP6 induced a significant analgesic effect while OP5
showed less activity. It is well known that formalin
model which is consider mimicking clinical pain [23],
has two main distinct phases. The first one characterized
as neurogenic pain is related to chemical stimulation of
Aδ and C fibers, the release of excitatory amino-acids,
nitric oxide and substance P while the second phase
known as inflammatory pain is related to the release of
bradykinin and prostaglandins [16, 24]. Drugs that in-
hibit only the first or both phases are considered as cen-
tral analgesics while those acting only at the second
phase are considered as peripheral analgesic drugs [25].
The mixture of cycloartanes as well as OP3 and OP6 sig-
nificantly inhibited both phases of formalin-induced pain
while OP5 inhibited predominately the first phase. The
activity of these compounds either taken individually or
as a mixture was significantly more potent at the first
phase than at the second. These results indicate that the
tested cycloartanes may be central acting molecules. The
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Fig. 8 Time-dependant acute (panel a) effect of Pallidioside B (OP5) and
Pallidioside C (OP6) and repeated treatment of OP5 (panel b) on
inflammation induced by formalin (2 %, 100 μl) injection in rat paw.
Animals were orally treated with different compounds and injected one
hour later with formalin. The diameter of the paw was measured before
treatment and after formalin injection. For chronic experiment, animals
were daily treated and the diameter of the paw was measured before
drug administration. Each point represents the mean ± SEM, n= 8.
*P < 0.05, **p < 0.01, ***p < 0.001 significant differences compared to the
control. Diclo: diclofenac
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structural difference between these compounds is at C-
24, which in the case of OP3 carries a ketone while that
of OP5 and OP6 carry a hydroxyl group. The combin-
ation of the structure and activity of molecules shows
that the substitution on C-24 by the ketone group or the
hydroxyl group does not significantly affect the analgesic
activity in the formalin model. However, the analgesic
activity on the inflammatory pain can be improved if the
hydroxyl group at C-24 is placed in front of the plane.
Acid hydrolysis leading to aglycone did not affect the
analgesic activity of different compounds on the neuro-
genic pain but significantly reduced the effect of OP6 on
the inflammatory pain. These results suggest a probable
interaction between the hydroxyl group and sugar, all
placed in front of the plane, which could be necessary
for the activity of OP6. This hypothesis is further sup-
ported by the results obtained after acetylating OP3, OP5
and OP6. In fact, the process has significantly inhibited
the analgesic activity of all these compounds. We can
then conclude that the hydroxyl groups attached to the
aglycone are responsible for the analgesic activity of
these cycloartanes, mainly as far as the inflammatory
pain is concern. These results corroborate those previ-
ously obtained by Ayatollahi et al. [12] who showed that
cycloartanes can deactivate protein Kinase C, thanks to
their hydroxyl group. In addition, it has been shown that
PKC mediates the phase 2 of formalin-induced pain [26].
Taking all together, it can be thought that cycloartanes
from Oxyanthus pallidus induced their analgesic effect by
inhibiting at least partially the activation of PKC.
OP5 and OP6 were further tested on mechanical hyper-
algesia and inflammation induced by formalin in rats. In
the acute test, they significantly reduced mechanical
hyperalgesia from the first hour after induction of pain
and lasted until the 24th hour post administration. OP5, in
contrary of OP6, showed a significant anti-inflammatory
effect only at the 3rd hour post treatment. These results
indicate that the analgesic effects of tested cycloartanes
are not dependent to their anti-inflammatory activity if
any. Furthermore, repeated treatment with OP5 did not
show any anti-inflammatory effect, demonstrating that
OP5 is devoid of anti-inflammatory effect.
It was observed that unlike diclofenac, repeated oral ad-
ministration of OP5 did not induce gastric ulceration and
did not significantly affect the gastric mucus weight.
Diclofenac reduces mucus production and induces gastric
ulcer through the reduction of prostaglandin resulting
from its inhibitory effect on cyclooxygenase. The above re-
sult suggests that OP5 do not inhibit cyclooxygenase.
The strong involvement of oxidative stress in inflamma-
tory and painful phenomena [27, 28] has motivated the
study of the in vivo antioxidant activity of OP5 in animals
treated chronically. OP5 significantly reduced malondial-
dehyde (MDA) and increased the level of superoxide dis-
mutase (SOD) without affecting the activity of catalase
and nitric oxide amount. These results suggest that OP5
Table 3 Effects of different treatments on the biochemical parameters of oxidative stress and hepatotoxicity
Parameters Tissue Control Diclofenac (5 mg/kg) OP5 (2.5 mg/kg) OP5 (5 mg/kg)
NO (μmol/g tissue) liver 0.49 ± 0.06 0.28 ± 0.06* 0.48 ± 0.04 0.36 ± 0.03
kidney 1.014 ± 0.11 0.66 ± 0.15 1.23 ± 0.15 0.85 ± 0.06
Glutathione (μmol/g tissue) liver 0.12 ± 0.01 0.11 ± 0.01 0.12 ± 0.01 0.10 ± 0.01
kidney 0.07 ± 0.01 0.04 ± 0.01 0.09 ± 0.01 0.07 ± 0.00
MDA (μmol/g tissue) liver 9.37 ± 0.74 9.80 ± 0.46 3.10 ± 0.37*** 9.42 ± 0.24
kidney 0.12 ± 0.01 0.09 ± 0.02 0.14 ± 0.01 0.12 ± 0.00
SOD (U/mg protein) liver 0.05 ± 0.01 0.12 ± 0.00* 0.08 ± 0.02 0.11 ± 0.01*
kidney 0.19 ± 0.08 0.12 ± 0.05 0.09 ± 0.02 0.10 ± 0.04
Catalase (U/mg protein) kidney 0.08 ± 0.01 0.08 ± 0.01 0.10 ± 0.02 0.08 ± 0.01
ALAT (U/mg protein) serum 0.39 ± 0.15 0.4 ± 0.01 0.60 ± 0.08 0.80 ± 0.21
ASAT (U/mg protein) serum 1.28 ± 0.10 1.58 ± 0.13 1.35 ± 0.07 1.313 ± 0.11
Each value represents the average ± ESM of eight animals.*p < 0.05, ***p < 0.001 significant difference compared to the control group
Table 4 Evaluation of the ulcerogenic activity of Diclofenac (Diclo) and OP5
Groups Doses (mg/kg) Mucus weight (mg) Total surface of stomach (mm2) ulcerated surface (mm2) % of ulcerated animals
Control 0.163 ± 0.013 1479.00 ± 72.79 0.00 ± 0.00 0
Diclo 5 0.073 ± 0.014* 1406.00 ± 78.92 221.10 ± 0.00*** 100
OP5 2,5 0.127 ± 0.018 1886.00 ± 127.00 0.00 ± 0.00 0
OP5 5 0.090 ± 0.009 1723.00 ± 46.90 0.00 ± 0.00 0
Each value represents the mean ± SEM of eight animals.*p < 0.05, ***p < 0.001 significant difference compared to the control group. Diclo diclofenac
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might potentiate the in vivo antioxidant capacity of the or-
ganism by increasing the SOD activity that could lead to re-
duction of lipid peroxydation. In other to evaluate the
impact of OP5 on the liver integrity, alanine aminotrasfer-
ase (ALAT) and aspartate aminotrasferase (ASAT) activities
were assayed in the serum. A dose dependent increase in
ALAT was observed in OP5 treated group, although not
significant. It is well known that plasma increase in ALAT
and ASAT, especially ALAT is a result of liver cells necrosis.
Thus, even though there was no evidence of hepatotoxic ef-
fect, caution should be taken when using OP5.
Conclusion
Cycloartanes isolated from Oxyanthus pallidus possess an-
algesic effects that are dissociated from anti-inflammatory
activity if any. The analgesic effect of these compounds es-
pecially the effect on inflammatory pain may be due to the
presence of hydroxyl group in front of the plane. Mean-
while, these cycloartanes are more potent on the neuro-
genic than on the inflammatory pain.
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